Transcatheter Systems Set To Dominate Heart Valve Market

Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.

Total worldwide sales of heart valve disease treatment systems are set to expand at a compound annual growth rate (CAGR) of 10.9%, increasing from approximately $4,8 billion in 2016 to an estimated $8.09 billion in 2021, according to "Heart Valve Repair and Replacement Devices Market", a June 2017 report from Informa's Meddevicetracker. Within that overall market, sales of heart valve disorder management products, which include percutaneous balloon valvuloplasty and surgical heart valve repair and replacement devices, will show a slight decline between now and 2021, while newer, less invasive and potentially safer techniques like transcatheter aortic valve replacement (TAVR) and mitral valve repair (TMVR) will continue to take market share.

Valvular heart disease occurs when there is inadequate opening or closing of an individual valve, sometimes accompanied by insufficiency or...

More from Market Intelligence

More from In Vivo